A randomized, open-label, study of the impact of two doses of subcutaneous recombinant IL-2 (Proleukin) [aldesleukin] on viral burden and CD4+ cell count in patients with HIV-1 infection and CD4+ cell counts greater than or equal to 300/mm3

Trial Profile

A randomized, open-label, study of the impact of two doses of subcutaneous recombinant IL-2 (Proleukin) [aldesleukin] on viral burden and CD4+ cell count in patients with HIV-1 infection and CD4+ cell counts greater than or equal to 300/mm3

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2009

At a glance

  • Drugs Aldesleukin (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Sep 2008 Actual end date (Aug 2007) added as reported by CT.gov
    • 29 Sep 2008 Status changed from active, no longer recruiting to completed as reported by CT.gov
    • 14 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top